恩华药业
(002262)
| 流通市值：191.51亿 | | | 总市值：219.51亿 |
| 流通股本：8.84亿 | | | 总股本：10.13亿 |
| 利润表 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 营业总收入 | 4,775,641,892.99 | 3,218,250,058.44 | 1,610,251,670.32 | 5,911,188,872.18 |
| 营业总成本 | 3,469,272,034.8 | 2,364,783,063.73 | 1,251,661,776.48 | 4,768,546,017.03 |
| 其他经营收益 | | | | |
| 营业利润 | 1,322,679,769.81 | 852,956,398.34 | 357,179,657.59 | 1,199,172,212.53 |
| 利润总额 | 1,305,578,973.53 | 845,819,248.06 | 355,723,802.83 | 1,173,082,351.13 |
| 净利润 | 1,144,796,179.19 | 740,305,782.6 | 317,601,675.65 | 1,054,901,758.25 |
| 每股收益 | | | | |
| 其他综合收益 | - | - | - | -1,986,860.16 |
| 综合收益总额 | 1,144,796,179.19 | 740,305,782.6 | 317,601,675.65 | 1,052,914,898.09 |
| 资产负债表 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 流动资产: | | | | |
| 流动资产合计 | 7,032,044,098.65 | 6,736,201,621.4 | 6,874,617,689.79 | 6,462,952,432.6 |
| 非流动资产: | | | | |
| 非流动资产合计 | 2,874,314,649.3 | 2,798,844,468.46 | 2,768,020,698.03 | 2,760,279,487.56 |
| 资产总计 | 9,906,358,747.95 | 9,535,046,089.86 | 9,642,638,387.82 | 9,223,231,920.16 |
| 流动负债: | | | | |
| 流动负债合计 | 1,049,339,674.21 | 1,083,285,672.84 | 1,207,335,486.62 | 1,092,239,535.19 |
| 非流动负债: | | | | |
| 非流动负债合计 | 87,500,146.42 | 89,283,998.92 | 89,805,192.76 | 103,096,352.18 |
| 负债合计 | 1,136,839,820.63 | 1,172,569,671.76 | 1,297,140,679.38 | 1,195,335,887.37 |
| 所有者权益(或股东权益): | | | | |
| 归属于母公司股东权益合计 | 8,799,139,163.18 | 8,391,502,914.79 | 8,374,548,528.42 | 8,057,134,574.75 |
| 股东权益合计 | 8,769,518,927.32 | 8,362,476,418.1 | 8,345,497,708.44 | 8,027,896,032.79 |
| 负债和股东权益合计 | 9,906,358,747.95 | 9,535,046,089.86 | 9,642,638,387.82 | 9,223,231,920.16 |
| 现金流量表 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 经营活动产生的现金流量: | | | | |
| 经营活动现金流入小计 | 5,266,025,401.65 | 3,325,597,254.47 | 1,516,171,770.38 | 6,433,556,634.04 |
| 经营活动现金流出小计 | 4,407,406,089.14 | 3,045,188,873.05 | 1,358,342,141.5 | 5,355,166,877.21 |
| 经营活动产生的现金流量净额 | 858,619,312.51 | 280,408,381.42 | 157,829,628.88 | 1,078,389,756.83 |
| 投资活动产生的现金流量: | | | | |
| 投资活动现金流入小计 | 5,797,275,426.85 | 3,863,241,590.08 | 1,591,215,444.74 | 6,863,707,235.34 |
| 投资活动现金流出小计 | 6,398,172,750.78 | 3,948,086,305.19 | 1,796,135,996.94 | 7,425,643,800.19 |
| 投资活动产生的现金流量净额 | -600,897,323.93 | -84,844,715.11 | -204,920,552.2 | -561,936,564.85 |
| 筹资活动产生的现金流量: | | | | |
| 筹资活动现金流入小计 | 90,000,000 | 90,000,000 | 61,000,000 | 30,000,000 |
| 筹资活动现金流出小计 | 583,225,975.68 | 503,032,583.51 | 38,126,739.71 | 416,097,700.19 |
| 筹资活动产生的现金流量净额 | -493,225,975.68 | -413,032,583.51 | 22,873,260.29 | -386,097,700.19 |
| 汇率变动对现金及现金等价物的影响 | 973,277.95 | 4,545,602 | 668,615.1 | -1,036,094.54 |
| 现金及现金等价物净增加额 | -234,530,709.15 | -212,923,315.2 | -23,549,047.93 | 129,319,397.25 |
| 期末现金及现金等价物余额 | 1,108,250,968.07 | 1,129,858,362.02 | 1,319,232,629.29 | 1,342,781,677.22 |
| 补充资料: | | | | |
| 现金及现金等价物的净增加额 | - | -212,923,315.2 | - | 129,319,397.25 |
最新报告期：2026-08-24| 研究机构 | 分析师 | 预测每股收益(元) | 更新日 |
| 2026年 | 2027年 | 2028年 |
| 西南证券 | 杜向阳 | 1.16 | 1.30 | 1.52 | 2026-08-24 |
| 中信建投 | 沈毅,袁清慧 | 1.17 | 1.32 | 1.50 | 2026-08-19 |
| 东吴证券 | 朱国广 | 1.14 | 1.29 | 1.46 | 2026-08-19 |
| 国金证券 | 甘坛焕 | 1.14 | 1.29 | 1.57 | 2026-08-18 |
| 华泰证券 | 代雯,李奕玮 | 1.15 | 1.33 | 1.53 | 2026-08-18 |